Nov. 25, 2025 -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted for inclusion in the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. The study, supported by a grant from the ALS Association, will be led b

Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode each year Nov. 24, 2025 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support clinical

First publicly listed company to actively investigate psilocybin’s potential impact on longevity Nov. 25, 2025 -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as the first – an

November 25, 2025 — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Commission (EC) has approved AVT03 as a biosimilar to Prolia® and Xgeva® (denosumab). The European denosumab market is currently valued at approximately US$1.2 billion across all indications, based on originator sales in the last 12 months including the second quarter of 2025[1]. Denosumab is widel

- 114 infants and toddlers received Persephone’s synbiotic or placebo - - The study generated important, positive clinical data on colonization and sleep improvement, after just 30 days of treatment - - Persephone’s synbiotic, designed to restore critical gut microbes in babies, was launched in September with a waitlist of 10,000 families - Nov. 20, 2025 -- Persephone Biosciences, a pioneering biotech company focused on unlocking the potential of the microbiome to impact human health, today an

Nov. 20, 2025 -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination immunotherapy platform for solid tumor cancers, today announced that an abstract has been accepted for presentation at the Society of Urologic Oncology (SUO) 26th Annual Meeting being held December 2-5, 2025 in Phoenix, Arizona. The abstract, titled, “Effective resolution of bone metastases in patients with metastatic prostate cancer using SYNC-T Therapy SV-102,

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens Evaxion’s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen demonstrates superior performance compared to the traditional gB antigen, including enhanced CMV neutralization Preclinical a

Nov. 20, 2025 -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP). The Com

Full Study Results Expected in Q1 2026 Further Clinical Development of NAV-240 in Hidradenitis Suppurativa to Begin in Early 2026 Nov. 20, 2025 -- Navigator Medicines Inc., a clinical-stage biotech company pioneering the advancement of best-in-class bispecific antibodies (bsAb) for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced successful completion of participant visits in the Phase 1b multiple-ascending dose study (MAD) of NAV-240. The Phase 1b t

Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that typically becomes harder to treat each time a patient relapses1,2 Lunsumio subcutaneous offers a new treatment option that can significantly reduce administration time to approximately one minute Availability of Lunsumio SC allows patients to receive treatment aligned to clinical requirements and lifestyle preferences 19 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) a